3.62

4.23% -0.16

After Hours: 3.69 0.07 +1.93%

Sab Biotherapeutics Inc (SABS)

Overview News Price History Financials Discussions Forecast

Sab Biotherapeutics Inc stock is traded at $3.62, with a volume of 602.36K. It is down -4.23% in the last 24 hours and up +3.13% over the past month. SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.

Previous Close:

$3.78

Open:

$3.78

24h Volume:

602.36K

Relative Volume:

0.91

Market Cap:

$329.37M

Revenue:

$114.70K

Net Income/Loss:

$-26.49M

P/E Ratio:

-1.4677

EPS:

-2.4665

Net Cash Flow:

$-53.17M

1W Performance:

-3.98%

1M Performance:

+3.13%

6M Performance:

-3.21%

1Y Performance:

+64.96%

1-Day Range:

$3.61

$3.78

1-Week Range:

$3.61

$3.88

52-Week Range:

$1.85

$5.15

Sab Biotherapeutics Inc Stock (SABS) Company Profile

Name

Sab Biotherapeutics Inc

Sector

Healthcare (1033)

Industry

Biotechnology (582)

Phone

305-845-2813

Address

777 W 41ST ST, MIAMI BEACH

Employee

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

SABS's Discussions on Twitter

Compare SABS vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SABS Sab Biotherapeutics Inc	3.62	336.65M	114.70K	-26.49M	-53.17M	-2.4665
VRTX Vertex Pharmaceuticals Inc	547.59	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	828.50	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,011.11	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	138.89	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	211.58	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-02-26	Initiated	Rodman & Renshaw	Buy
Dec-19-25	Initiated	Guggenheim	Buy
Sep-17-25	Initiated	Leerink Partners	Outperform
May-14-25	Resumed	H.C. Wainwright	Buy
Oct-09-24	Initiated	Craig Hallum	Buy
Aug-28-24	Initiated	Oppenheimer	Outperform
Nov-05-21	Initiated	Chardan Capital Markets	Buy

View All

Sab Biotherapeutics Inc Stock (SABS) Latest News

Aug 21, 2026

Price to earnings forward of SAB Biotherapeutics, Inc. – BOATS:SABSW - TradingView

Aug 21, 2026

Aug 20, 2026

Balyasny Asset Management L.P. Expands Stake in SAB Biotherapeutics Inc (SABS) - GuruFocus

Aug 20, 2026

SAB (SABS) Earnings Update: EPS Prints Above Forecast in the Current Update; Market Move: Shares Move Lower 0.26% in the Latest SessionROE Trend Analysis - vinanet.vn

Aug 20, 2026

Aug 16, 2026

SAB Biotherapeutics (SABS) Slips 1.33% to $3.70 as Support Level Comes into FocusCash Flow Strong Stocks - vinanet.vn

Aug 16, 2026

Aug 14, 2026

Perceptive Advisors discloses 7.3% SAB Biotherapeutics (SABS) stake via Master Fund - Stock Titan

Aug 14, 2026

Caligan Partners (SABS) discloses 7.97M SAB Biotherapeutics shares in amended 13G - Stock Titan

Aug 14, 2026

Commodore Capital discloses 8.95M-share position in SAB Biotherapeutics (SABS) - Stock Titan

Aug 14, 2026

Vivo funds (SABS) report capped 9.99% stakes via preferred stock and warrants - Stock Titan

Aug 14, 2026

Woodline Partners (SABS) discloses 5.46M-share beneficial stake in SAB Biotherapeutics - Stock Titan

Aug 14, 2026

Balyasny Asset Management (SABS) discloses 7.2M-share SAB Biotherapeutics position capped at 9.99% - Stock Titan

Aug 14, 2026

Aug 12, 2026

Adage discloses 8.38% SAB Biotherapeutics (SABS) ownership in Schedule 13G - Stock Titan

Aug 12, 2026

Aug 11, 2026

SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Aug 11, 2026

Aug 10, 2026

RA Capital group discloses 9.9% SAB Biotherapeutics (SABS) stake capped by ownership blockers - Stock Titan

Aug 10, 2026

Q3 EPS Estimate for SAB Biotherapeutics Boosted by Analyst - MarketBeat

Aug 10, 2026

What is HC Wainwright's Estimate for SABS Q3 Earnings? - MarketBeat

Aug 10, 2026

SAB Biotherapeutics (NASDAQ:SABS) Upgraded by Wall Street Zen to "Sell" Rating - MarketBeat

Aug 10, 2026

Aug 08, 2026

H.C. Wainwright Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $10 - Moomoo

Aug 08, 2026

Aug 07, 2026

SAB Biotherapeutics Q2 Earnings Call Highlights - MarketBeat

Aug 07, 2026

SABS FY2030 EPS Boosted by Brookline Capital Markets - marketbeat.com

Aug 07, 2026

Aug 06, 2026

SAB Biotherapeutics (NASDAQ:SABS) Posts Earnings Results, Hits Estimates - MarketBeat

Aug 06, 2026